Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 5;21(Suppl 1):114.
doi: 10.1186/s12969-023-00864-1.

The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease

Peter A Nigrovic  1   2 , Fabrizio de Benedetti  3 , Yukiko Kimura  4 , Daniel J Lovell  5 , Sebastiaan J Vastert  6
Affiliations

The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease

Peter A Nigrovic et al. Pediatr Rheumatol Online J. .

Abstract

Currently, the criteria used to classify patients with SJIA are different from those used for AOSD. However, it has been recognized that the existing terms are too narrow, subdividing the Still's population unnecessarily between pediatric-onset and adult-onset disease and excluding an appreciable group of children in whom overt arthritis is delayed or absent. Government regulators and insurers rely upon the guidance of subject experts to provide disease definitions, and when these definitions are flawed, to provide new and better ones. The classification session at the NextGen 2022 conference helped to serve this purpose, establishing the need for a revised definitional system that transcends the fault lines that remain in existing definitions.

Keywords: AOSD; SJIA; SJIA diagnostic criteria; Still’s Disease.

PubMed Disclaimer

Conflict of interest statement

PAN received investigator-initiated research grants from Bristol-Myers Squibb (BMS), Pfizer, and Novartis; consulting from BMS, Cerecor, Exo Therapeutics, Miach Orthopedics, Novartis, and Pfizer; royalties from UpToDate Inc. and the American Academy of Pediatrics; and salary support from the Childhood Arthritis and Rheumatology Research Alliance. FDB has received research grants from SOBI, Novartis, Roche, Sanofi, consultancies from Sobi, Novartis.

Roche. YK has received investigator-initiated research grant support (awarded to CARRA) from Genentech, Inc., and served on an advisory board for SOBI; royalties from UpToDate Inc, and salary support from the Childhood Arthritis and Rheumatology Research Alliance. DJL’s institution, the Cincinnati Children’s Hospital Medical Center, has received research grants from BMS, Janssen, Novartis, Pfizer Inc., Roche and UBC; and has received consulting fees or other remuneration from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer Inc., Roche, and UBC for the work of DJL. DJL is a member of the Data Safety and Monitoring Boards for studies funded by the National Institutes of Health and the Canadian Arthritis Society. SJV received investigator-initiated research grants from SOBI and consultancy/speaker fees from SOBI and Novartis.

References

    1. Still GF. On a Form of Chronic Joint Disease in Children. Med Chir Trans. 1897;80:47–60. doi: 10.1177/095952879708000106. - DOI - PMC - PubMed
    1. Brewer EJ, Jr, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977;20(2 Suppl):195–9. - PubMed
    1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392. - PubMed
    1. Case SM, Nigrovic PA. Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis. Paediatr Drugs. 2022;24(3):185–91. - PMC - PubMed
    1. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424–430. - PubMed